Industry Trends

Will the politically fueled reforms and mandates around drug pricing reduce the complexity of the system?

Dr. Bruce Leuchter, CEO of Neurvati Neurosciences, continues his conversation, this time looking to the upcoming year in neuroscience.

Novo Nordisk’s board overhaul signals a decisive return to Foundation-led scientific and operational governance, raising strategic questions about whether the company can sustain U.S. growth and consumer-market leadership in the GLP-1 era without deeper American commercial expertise.

A Q&A with Christopher Stanton, Ph.D., Marvin Bower Associate Professor of Business Administration at Harvard Business School.

Q&A with Harry Totonis, CEO and chairman of ConnectiveRx, on embracing change and seeking better solutions amid today’s challenging playing field for patient access.

A Harvard Business School Healthcare Alumni Association Q&A with Jennifer McCollum, CEO of Catalyst.

The arrival of GLP-1 receptor agonists and dual agonists has delivered unprecedented efficacy, reframed obesity as a chronic disease, and sparked an industry gold rush.

Ryan Quigley, CEO of Inizio, explains how AI, personalized medicine, and GLP 1s are shaping commercialization trends.

Drugmaker aims to simplify operations, speed up decision-making, and reinvest savings into diabetes and obesity growth opportunities in latest round of pharma layoffs.

The global biotherapeutics company announced that it will seek to streamline operations as part of a broader transformation to boost efficiency, refocus on core businesses, and reinvest in high-priority programs.

Fate Therapeutics, Generation Bio, and ORIC Pharmaceuticals join a growing list of companies implementing workforce reductions as they restructure operations, extend cash runways, and focus resources on advancing lead clinical programs amid challenging market conditions.

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and oncology medicines, with construction beginning in 2025 and operations slated for 2027.

The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 outlook on the strength of key pharmaceutical products.

A Harvard Business School Healthcare Alumni Association Q&A with Stephanie J. Creary, Assistant Professor of Management at The Wharton School of The University of Pennsylvania.

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales producers, its 25th, points to the importance of organizations doubling down on what they do best while seizing new opportunities to innovate.

Dive into a sampling of data drivers—and expanded insights—poised to impact and reshape our annual leaderboard.

Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through transparency, storytelling, and leveraging data to improve patient care.

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in its strategic plans amid recent market challenges.

Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar gaps, reimbursement pressure from GLP-1s, and persistent access challenges.

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.